GlassScriptPhysician profile
Sumalatha Nandikonda
NPI 1174842017
$4,462.40
in general payments reported to CMS, 2019-2025
21 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $434 · 2021: $1,163 · 2022: $1,671 · 2023: $617 · 2024: $196 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.53 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,123.29 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $895.10 | 2020-2025 | |
| Amgen INC. | $439.57 | 2020-2025 | Enbrel, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $356.33 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.12 | 2021-2022 | |
| Ucb, INC. | $192.33 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $177.95 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $172.38 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $146.12 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $129.83 | 2022-2023 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $128.56 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $125.92 | 2020-2022 | |
| Lilly USA, LLC | $93.00 | 2020-2021 | |
| Genentech USA, INC. | $84.77 | 2021-2022 | |
| Horizon Therapeutics Plc | $43.47 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.98 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.42 | 2022 | |
| Sobi, INC | $21.16 | 2025 | |
| Invivyd INC | $21.06 | 2025 | Pemgarda |
| Daiichi Sankyo INC. | $19.61 | 2021 | |
| Mylan Institutional INC. | $17.43 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumalatha Nandikonda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.